Canadian biotechnology firm Biomira Inc and venture capitalists Almiria have said the latter will distribute 7,612,809 common shares of Biomira to its 35 shareholders. Included in the distribution are 3,732,166 shares which were issued to Almiria pursuant to the previously-announced amalgamation of Bioalta Inc and a subsidiary of Biomira, but this does not affect the total outstanding common shares of Biomira which remain at 22,522,537.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze